Abstract
To predict prognoses of AML patients prior to the start of chemotherapy and to classify them according to their predicted prognoses, we analyzed the data on 545 (90%) patients out of 606 patients who were enrolled in the JALSG AML-87 or -89 protocol. Median age was 48 years. AML subtypes were as follow; AML-M1 was 96 (17.6%), M2 196 (36.0%), M3 107 (19.6%), M4 95 (17.4%), M5 31 (5.7%), M617 (3.1%) and M7 3 (0.6%). Eighty-nine patients(16%) were diagnosed as having trilineage dysplasia (TLD). We could elucidate seven good prognostic factors using multivariate analysis and gave them the weighted scores such as +2; ≤50 years of age, ≤ 20 000/mm3 of WBC, ≥ 50% of myeloperoxidase (MPO) positivity of blasts and presence of Auer bodies and +1; absence of TLD, FAB subtypes of AML-M2 or -M3 or -M4 with eosinophilia and ≤30 IU/l of serum glutamic oxaloacetic transaminase (GOT). A scoring system could classify the patients into three groups such as good (total scores; +9~+11) (149 cases, 53% at 5 years-survival), intermediate (+5~+8) (175 cases, 29%) and poor risk (0~+4) (95 cases, 10%). This system will be tested for feasibility in the next AML-92 protocol (about 700 cases) prospectively. If this procedure proves feasible, clinical trials could be designed based on such a risk group-stratification.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Dastugue N, Payen C, Lafage-Pochitaloff M, Bernard P, Leroux D, Huguet-Rigal F, Stoppa A-M, Marit G, Molina L, Michallet M, Maraninchi D, At-tal M, Reiffers J (1995) Prognostic significance of karyotype in de novo adult acute myeloid leukemia. Leukemia 9: 1491–1498
Ohno R, Kobayashi T, Tanimoto M, Hiraoka A, Imai K, Asou N, Tomonaga M, Tsubaki K, Takahashi I, Kodera Y, Yoshida, M, Murakami H, Naoe T, Shimoyama M, Tsukada T, Takeo T, Teshima H, Onozawa Y, Fujimoto K, Kuriyama K, Horiuchi A, Kimura I, Minami S, Minra Y, Kageyama S, Tahara T, Masaoka T, Shirakawa S, Saito H (1993) Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. Cancer 71: 3888–3895
Kobayashi T, Miyawaki S, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, Minato K, Tsubaki K, Ohmoto E, Oh H, Jinnai I, Sakamaki H, Hiraoka A, Kanamaru A, Takahashi I, Saito K, Naoe T, Yamada O, Asou N, Kageyama S, Emi N, Matsuoka A, Tomonaga M, Saito H, Ueda R, Ohno R (1996) Randomized trials between Behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. J Clin Oncol 14: 204–213
Bennett JM, Catovsky D, Daniel MT, Flandrin J, Galton DAG, Gralnick HR, Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103: 626–629
Brito-Babapulle F, Catovsky D, Galton DAG (1987) Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodysplasia. Br J Haematol 66: 445–450
Kuriyama K, Tomonaga M, Matsuo T, Kobayashi T, Miwa H, Shirakawa S, Tanimoto M, Adachi K, Emi N, Hiraoka A, Tominaga N, Imai K, Asou N, Tsubaki K, Takahashi I, Minami S, Yoshida M, Murakami H, Minato K, Ohshima T, Furusawa S, Ohno R (1994) Poor response to intensive chemotherapy in acute myeloid leukaemia with trilineage myelodysplasia. Br J Heamatol 86: 767–773
Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kobayashi T, Kuriyama K, Ohmoto E, Sakamaki H, Tsubaki K, Hiraoka A, Yamada O, Oh H, Saito K, Matsuda S, Minato K, Ueda T, Ohno R (1995) All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 85: 1202–1206
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Kuriyama, K. et al. (1998). Trial to Extract Prognostic Factors Prior to the Start of Induction Chemotherapy for Adult AML. In: Hiddemann, W., et al. Acute Leukemias VII. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 39. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71960-8_125
Download citation
DOI: https://doi.org/10.1007/978-3-642-71960-8_125
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-71962-2
Online ISBN: 978-3-642-71960-8
eBook Packages: Springer Book Archive